Virtual Library
Start Your Search
Jose Sanz Santos
Author of
-
+
OA10 - Sophisticated TNM Staging System for Lung Cancer (ID 136)
- Event: WCLC 2019
- Type: Oral Session
- Track: Staging
- Presentations: 1
- Now Available
- Moderators:Ke-Neng Chen, Pedro Lopez De Castro
- Coordinates: 9/09/2019, 14:00 - 15:30, Toronto (1985)
-
+
OA10.07 - Concordance Between ROSE and Final Diagnosis in Patients Undergoing EBUS- TBNA for Non-Small Cell Lung Cancer Staging (Now Available) (ID 1123)
14:00 - 15:30 | Author(s): Jose Sanz Santos
- Abstract
- Presentation
Background
In patients with non-small cell lung cancer (NSCLC) undergoing mediastinal staging through endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) clinical decision making is based in rapid on-site evaluation (ROSE) findings. We aimed to analyze the accuracy of ROSE determining the rate of concordance between ROSE and final diagnosis.
Method
Prospective study that included patients undergoing EBUS-TBNA for NSCLC staging. Results of ROSE were compared with final diagnosis.
Result
Sixty-four patients were included and 637 lymph nodes (LN) were sampled: a median of 10 (IQR 8-12) LNs and a median of 5 (IQR: 4-6) nodal stations per patient were sampled. The diagnoses of ROSE were concordant with the final diagnoses in 612 (96.1%) cases and non-concordant in 25 (3.9%). There were 7 (1.2%) LNs in which the diagnosis of ROSE was non-malignant with a final diagnosis of malignancy. On the contrary, there was a single case (0.2%) in which the diagnosis of ROSE was malignant with the final diagnosis being normal LN. Considering final diagnosis as the gold standard, the sensitivity, specificity and overall accuracy of ROSE were 98.6, 97.2 and 98.5% respectively.
Table 1:
ConclusionDIAGNOSIS
ROSE
FINAL DIAGNOSIS
Non-diagnostic/
Inadequate
(82)
Benign/
Normal lymph node (520)
Malignancy
(36)
Non-diagnostic/
Inadequate
(70)
67
3
0
Benign/
Normal lymph node (526)
14
511
1
Malignancy
(42)
1
6
35
The preliminary diagnoses (ROSE) are concordant with the final diagnoses in a high percentage. Consequently, clinical decisions based on the ROSE can be taken with confidence.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P1.13 - Staging (ID 181)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Staging
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.13-10 - Incidence of Hidden Extrathoracic Metastases and Unexpected Second Malignancies Detected by PET in Patients with Lung Cancer (ID 1699)
09:45 - 18:00 | Author(s): Jose Sanz Santos
- Abstract
Background
Recent staging guidelines for lung cancer (LC) staging recommend invasive mediastinal staging regardless of the findings of positron emission tomography (PET). Thus, the role of PET in the staging of LC seems to be increasingly relegated to the detection of hidden extrathoracic metastases. The aim of the study was to determine the incidence of hidden metastasis and second malignancies diagnosed by PET in a cohort of patients with LC and without extrathoracic metastases identified in the initial radiologic work up.
Method
This is a retrospective study that included patients with a final diagnosis of LC without extrathoracic metastases identified in the initial radiologic work up (thorax and upper abdomen computer tomography). The incidence of hidden metastases and unexpected second malignancies detected by PET were recorded.
Result
From 2006 to 2018, 343 patients were included (81% male, mean age 68.2 ± 9.6 years) (Table 1). PET detected hidden metastases in 57 (16.6%) patients (Table 2). Fifty-two patients had a single metastasis and 5 had multiple metastases. A total of 64 metastases were detected, the most frequent location was bone (28). Five (1.4%) patients presented an unexpected second malignancy: 2 head and neck, 2 colorectal and one lymphoma.
Conclusion
PET detects hidden metastases in 16% of patients with LC and without extrathoracic metastases identified in the initial radiologic work up. 1.4% patients presented an unexpected second malignancy.
